Literature DB >> 20370455

Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss.

Gang Wang1, Fernand Mac-Moune Lai, Ka-Bik Lai, Kai-Ming Chow, Bonnie Ching-Ha Kwan, Kam-Tao Philip Li, Cheuk-Chun Szeto.   

Abstract

BACKGROUND: Podocyte loss plays an important role in the pathogenesis of diabetic nephropathy, but counting the number of glomerular podocyte in renal biopsy specimen is a labor-intensive task. We study whether intra-renal and urinary messenger RNA expression of podocyte-associated molecules could be used to estimate glomerular podocyte number in patients with diabetic nephropathy.
METHOD: We studied 21 consecutive patients with biopsy-proven diabetic nephropathy. The intra-renal and urinary mRNA expression of nephrin, podocin, and synaptopodin were measured by real-time quantitative polymerase chain reaction. Podocyte number was determined in micro-dissected glomerulus. The degree of histological scarring was quantified by morphometric analysis.
RESULTS: Glomerular podocyte number correlated with intra-renal expression of nephrin (r=0.510, p=0.044), podocin (r=0.605, p=0.013), and synaptopodin (r=0.480, p=0.060). Glomerular podocyte number also significantly correlated with urinary expression of synaptopodin (r=0.595, p=0.019) but not other targets. Baseline renal function correlated with intra-renal expression of nephrin (r=0.617, p=0.005), synaptopodin (r=0.474, p=0.040), and podocin (r=0.443, p=0.057). The degree of tubulointerstitial scarring also inversely correlated with intra-renal expression of nephrin (r=-0.462, p=0.047), podocin (r=-0.458, p=0.049), and synaptopodin (r=-0.500, p=0.029) but not with urinary gene expression.
CONCLUSION: Intra-renal expression of podocyte-associated molecules correlated with glomerular podocyte number, renal function, and tubulointerstitial scarring. The results suggest that intra-renal, but not urinary expression of podocyte-associated molecules, might be used to assess the degree of podocyte loss in diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370455     DOI: 10.3109/08860221003611737

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

Review 1.  Podocytes from the diagnostic and therapeutic point of view.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pflugers Arch       Date:  2017-05-16       Impact factor: 3.657

2.  Expression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathies.

Authors:  Patrícia Garcia Rodrigues; Rafael Nazário Bringhenti; Jonathan Frapporti do Nascimento; Gabriel Joelsons; Mariane dos Santos; Sane Pereira; Francisco Veríssimo Veronese
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

3.  Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.

Authors:  Vinita Agrawal; Narayan Prasad; Manoj Jain; Rakesh Pandey
Journal:  Clin Exp Nephrol       Date:  2013-02-02       Impact factor: 2.801

4.  Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy.

Authors:  Min Zheng; Lin-Li Lv; Jie Ni; Hai-Feng Ni; Qing Li; Kun-Ling Ma; Bi-Cheng Liu
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

5.  Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.

Authors:  Ligia Petrica; Sorin Ursoniu; Florica Gadalean; Adrian Vlad; Gheorghe Gluhovschi; Victor Dumitrascu; Daliborca Vlad; Cristina Gluhovschi; Silvia Velciov; Flaviu Bob; Petru Matusz; Oana Milas; Alina Secara; Anca Simulescu; Roxana Popescu
Journal:  Diabetol Metab Syndr       Date:  2017-05-06       Impact factor: 3.320

Review 6.  A compendium of urinary biomarkers indicative of glomerular podocytopathy.

Authors:  Miroslav Sekulic; Simona Pichler Sekulic
Journal:  Patholog Res Int       Date:  2013-11-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.